Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Pfizer

Status and phase: Completed; Phase 2

Conditions: Carcinoma, Non Small Cell Lung

Treatments: Drug: PF-00299804

Study type: Interventional

Funder types: Industry

Identifiers

NCT00553254

A7471003

Details and patient eligibility

About

To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.

Enrollment: 55 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced NSCLC
• Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib or gefitinib
• Prior treatment with no more than two chemotherapy regimens, including adjuvant treatment
• Measurable disease

Exclusion criteria

• Chemotherapy, radiotherapy, biological or investigational agents within 4 weeks of baseline disease assessment
• Patients who lack of tolerance of erlotinib therapy
• Patients with known brain Metastases
• Patients with demonstrated history of or presence of interstitial lung disease.

Trial design

55 participants in 1 patient group

1

Experimental group

Treatment:

Drug: PF-00299804